Aker BioMarine (AKBM) Stock Overview
A biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for AKBM from our risk checks.
AKBM Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aker BioMarine ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 130.20 |
| 52 Week High | NOK 136.40 |
| 52 Week Low | NOK 78.80 |
| Beta | 0.33 |
| 1 Month Change | 7.43% |
| 3 Month Change | 32.59% |
| 1 Year Change | 45.47% |
| 3 Year Change | 204.56% |
| 5 Year Change | 210.00% |
| Change since IPO | 24.36% |
Recent News & Updates
AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside
Analysts have slightly lowered their price target for Aker BioMarine to NOK 124.91, reflecting modestly revised assumptions around long term revenue growth, profit margins, and a somewhat lower future P/E multiple. What's in the News for Aker BioMarine Aker BioMarine ASA secured a new contract for the supply of Lysoveta, with a contract value of about US$4 million in 2026 and expectations for higher volumes in 2027, according to a client announcement.AKBM: Higher Margins And Premium Multiple Will Support Stronger Future Upside
Analysts have lifted their price target on Aker BioMarine from NOK 69.22 to NOK 124.91, citing updated assumptions that keep revenue growth broadly similar while reflecting higher expected profit margins and a higher future P/E multiple. What's in the News Aker BioMarine ASA has secured a new contract for the supply of Lysoveta with an estimated value of about US$4 million in 2026, and the company reports that gross margin on Lysoveta is significantly higher than for Superba Krill Oil.Recent updates
AKBM: Higher Margin Contract Wins Will Support Stronger Future Upside
Analysts have slightly lowered their price target for Aker BioMarine to NOK 124.91, reflecting modestly revised assumptions around long term revenue growth, profit margins, and a somewhat lower future P/E multiple. What's in the News for Aker BioMarine Aker BioMarine ASA secured a new contract for the supply of Lysoveta, with a contract value of about US$4 million in 2026 and expectations for higher volumes in 2027, according to a client announcement.AKBM: Higher Margins And Premium Multiple Will Support Stronger Future Upside
Analysts have lifted their price target on Aker BioMarine from NOK 69.22 to NOK 124.91, citing updated assumptions that keep revenue growth broadly similar while reflecting higher expected profit margins and a higher future P/E multiple. What's in the News Aker BioMarine ASA has secured a new contract for the supply of Lysoveta with an estimated value of about US$4 million in 2026, and the company reports that gross margin on Lysoveta is significantly higher than for Superba Krill Oil.Does Aker BioMarine (OB:AKBM) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aker BioMarine (OB:AKBM) Is Finding It Tricky To Allocate Its Capital
To avoid investing in a business that's in decline, there's a few financial metrics that can provide early indications...Analysts Lift Aker BioMarine Price Target on Improved Profit Margins and Key Customer Win
Analysts have raised their price target for Aker BioMarine from NOK 61.60 to NOK 69.22, citing improved profit margin expectations as a key factor that supports the revised valuation. What's in the News Aker BioMarine ASA has been dropped from the S&P Global BMI Index (Key Developments) The company has secured new business with a customer for the supply of Superba Krill Oil.Would Aker BioMarine (OB:AKBM) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...There's Reason For Concern Over Aker BioMarine ASA's (OB:AKBM) Price
OB:AKBM 1 Year Share Price vs Fair Value Explore Aker BioMarine's Fair Values from the Community and select yours When...Need To Know: The Consensus Just Cut Its Aker BioMarine ASA (OB:AKBM) Estimates For 2025
Market forces rained on the parade of Aker BioMarine ASA ( OB:AKBM ) shareholders today, when the analysts downgraded...Aker BioMarine ASA's (OB:AKBM) CEO Compensation Looks Acceptable To Us And Here's Why
Key Insights Aker BioMarine's Annual General Meeting to take place on 25th of April Total pay for CEO Matts Johansen...Is Aker BioMarine (OB:AKBM) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Partnerships In Japan And China Will Expand Kori Brand's International Reach
Divesting Understory should streamline operations and enhance net margins, as the company refocuses on core segments like Human Health Ingredients.Aker BioMarine AS' (OB:AKBM) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
The Aker BioMarine AS ( OB:AKBM ) share price has done very well over the last month, posting an excellent gain of 34...Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Despite announcing strong earnings, Aker BioMarine AS' ( OB:AKBM ) stock was sluggish. We did some digging and found...Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors
Aker BioMarine AS' ( OB:AKBM ) price-to-sales (or "P/S") ratio of 1.1x may look like a pretty appealing investment...At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?
While Aker BioMarine AS ( OB:AKBM ) might not have the largest market cap around , it saw a significant share price...Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking
Aker BioMarine AS ( OB:AKBM ) shares have continued their recent momentum with a 25% gain in the last month alone. The...What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates
The latest analyst coverage could presage a bad day for Aker BioMarine AS ( OB:AKBM ), with the analysts making...There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues
Aker BioMarine AS' ( OB:AKBM ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy right now compared...There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)
Today we will run through one way of estimating the intrinsic value of Aker BioMarine AS ( OB:AKBM ) by taking the...Shareholder Returns
| AKBM | NO Food | NO Market | |
|---|---|---|---|
| 7D | -3.8% | 1.1% | 0.8% |
| 1Y | 45.5% | -9.0% | 22.7% |
Return vs Industry: AKBM exceeded the Norwegian Food industry which returned -10.1% over the past year.
Return vs Market: AKBM exceeded the Norwegian Market which returned 22.6% over the past year.
Price Volatility
| AKBM volatility | |
|---|---|
| AKBM Average Weekly Movement | 4.8% |
| Food Industry Average Movement | 4.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.6% |
Stable Share Price: AKBM has not had significant price volatility in the past 3 months compared to the Norwegian market.
Volatility Over Time: AKBM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 258 | Matts Johansen | www.akerbiomarine.com |
Aker BioMarine ASA, a biotech innovator, develops and supplies krill-derived products for consumer health and wellness worldwide. It operates through three segments: Human Health Ingredients (HHI), Consumer Health Products, and Emerging Business. The Human Health Ingredients segment sells B2B krill oil supplements for humans under the Superba Krill brand; supplements for brain health under the LYSOVETA brand; and marine-origin DHA omega-3 from microalgae under the Revervia brand name, as well as advanced phospholipid technology under PL+ name.
Aker BioMarine ASA Fundamentals Summary
| AKBM fundamental statistics | |
|---|---|
| Market cap | NOK 11.42b |
| Earnings (TTM) | -NOK 92.91m |
| Revenue (TTM) | NOK 2.11b |
Is AKBM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKBM income statement (TTM) | |
|---|---|
| Revenue | US$227.20m |
| Cost of Revenue | US$124.90m |
| Gross Profit | US$102.30m |
| Other Expenses | US$112.30m |
| Earnings | -US$10.00m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Oct 29, 2026
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 45.03% |
| Net Profit Margin | -4.40% |
| Debt/Equity Ratio | 150.7% |
How did AKBM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 01:57 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aker BioMarine ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Stein Aukner | DNB Carnegie |
| Ola Trovatn | DNB Carnegie |